Healthcare-focused venture capital firm Gilde has become a new investor in Definiens, a Munich-based company that specialises in image analysis for digital pathology, after leading a €10m financing round for the business.
Existing investors including TVM, Cipio and Definiens’ management also participated in the round.
Definiens said it will primarily use the funding for commercial expansion of its current business and to develop and commercialise innovative products for clinical digital pathology.
The company’s products are currently being used for research and development by all major pharmaceutical companies, as well as an increasing number of diagnostic companies in tissue-based diagnostic biomarker development.
“Digital Pathology combined with the right image analysis tools has the potential to transform cancer diagnosis,” said Dr Janke Dittmer, pictured, a partner at Gilde Healthcare Partners, who has also joined the Definiens supervisory board following the round.
“As the market leader in image analysis for Digital Pathology Definiens is well positioned to unlock the full potential of tissue based diagnostics and drive the clinical adoption of quantitative digital pathology.”
“We led this investment round because we believe that Definiens has a set of market leading products, a strong patent portfolio and unique capabilities to turn new concepts into clinically relevant products which will benefit people suffering from cancer around the world.”
Definiens is the brainchild of founder, CTO and Nobel Laureate Prof Dr Gerd Binnig.
Its context-based segmentation approach leads to more accurate detection of structures of interest and is robust with regard to variations in the tissue and the scanner used.
Copyright © 2012 AltAssets